News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Clene Inc. director Arjun JJ Desai was granted 3,674 stock options on August 13, 2026, with an exercise price of $4.19 per share. These options, granted under the Clene Inc. Amended 2020 Stock Plan, vest immediately and expire on August 12, 2036. This transaction …
Clene reported a significant widening of its Q2 FY26 net loss to $13.42 million, an 81% increase from the previous year, primarily due to a rise in total other expenses. Despite this, revenue saw an increase to $90,000, driven by product revenue, while operating …
Clene Inc. (CLNN) reported a Q2 loss of $0.6 per share, which was wider than the Zacks Consensus Estimate of a $0.37 loss, though an improvement from the $0.78 loss per share a year ago. The company exceeded revenue expectations, posting $0.09 million against …
Clene reported Q2 2026 financial results and provided updates on its ALS program, CNM-Au8. The company plans to submit a New Drug Application for CNM-Au8 in early Q4 2026 under the FDA's accelerated approval pathway, supported by new biomarker analyses showing improved survival and …
Clene Inc. reported a widened Q2 2026 net loss of $13.4 million, or $1.08 per share, compared to $7.4 million, or $0.78 per share, in Q2 2025. Despite the increased loss, the company is preparing to submit a New Drug Application (NDA) for its …
Clene is preparing to submit a new drug application (NDA) in early Q4 for CNM-Au8 as a potential treatment for ALS, following discussions with the FDA. The company's approach centers on neurofilament light (NfL) as a biomarker, having observed a 10% reduction in NfL …
Chidozie Ugwumba, an investor in Clene Inc. (CLNN), has filed an amended Schedule 13G reporting 0% beneficial ownership of the company's common stock. This change occurred because management of the investment portfolio for SymBiosis II, LLC, through which Ugwumba previously held shares, was transferred …
Clene Inc. (NASDAQ:CLNN) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $33.25. Despite this, the company's shares opened at $5.16, down 2.3%, and remain significantly below their 52-week high. Recent financial results for Clene Inc. fell …
Empery Asset Management, LP initiated a new position in Clene Inc (CLNN), purchasing over 916,000 shares, despite the stock being deemed "Significantly Overvalued" by GuruFocus and experiencing a 16.17% decline since the purchase date. Clene Inc is a clinical-stage pharmaceutical company specializing in nanotechnology …
Clene Inc. announced that new analyses of biomarker data from its CNM-Au8® trials will be included in its New Drug Application (NDA) for accelerated approval in ALS. These analyses show that patients treated with CNM-Au8 whose neurofilament light chain (NfL) levels declined or stabilized …
Clene Inc. announced positive results from analyses of its Phase 2 ALS trials, showing that patients treated with CNM-Au8 who had declining or stabilized neurofilament light chain (NfL) biomarker levels experienced a significant survival benefit. Participants in the HEALEY ALS Platform Trial showed a …
Clene Inc. (CLNN) is scheduled to announce its Q2'26 earnings on August 17th. The company anticipates a revenue of 61.00 thousand USD and an EPS of (0.37) USD for the quarter. Investors can find more detailed financial information on the CLNN Financials page.
This article from Investing.com announces the filing of a Form 8K by Clene Inc. for August 10th. The brief piece is a direct report of the regulatory filing and includes no further details or analysis beyond this announcement. It serves as a notification to …
Clene Inc. (CLNN) announced new post hoc biomarker analyses for its CNM-Au8 drug in ALS, demonstrating that patients with declining or stabilized neurofilament light chain (NfL) levels experienced significantly longer survival and better functional outcomes. These findings will support a planned New Drug Application …
Clene Inc. (CLNN) has an earnings forecast score of 8.00, ranking 171 out of 387 in its industry, with an average analyst price target of $30.00. Analysts largely recommend a "Buy" for the stock, anticipating a significant upside. The company's next expected revenue is …
Clene Inc. insider Chidozie Ugwumba has reported a disposal of beneficial ownership of warrants for 799,358 common shares, held indirectly through SymBiosis II LLC, due to a restructuring. Management of the fund's portfolio transferred to an unaffiliated third party, meaning Ugwumba no longer has …
Empery Asset Management, LP and Ryan M. Lane have disclosed a 7.17% beneficial ownership stake in Clene Inc. (CLNN) through a Schedule 13G SEC filing. This stake represents 916,532 shares of common stock, based on 12,778,307 shares outstanding as of May 11, 2026. The …
This article provides a comprehensive stock analysis of Clene Inc. (CLNN) based on TradingKey's Stock Score. It highlights the company's relatively stable fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite recent weak market performance, CLNN shows strong …
Clene Inc. (Nasdaq: CLNN), a biopharmaceutical company specializing in neurodegenerative diseases, announced its management will present at the Canaccord 46th Annual Growth Conference on August 11, 2026, at 10:30 AM ET in Boston. The company focuses on improving mitochondrial health and protecting neuronal function …
Clene Inc. announced that its management will present at the Canaccord 46th Annual Growth Conference and hold 1x1 investor meetings on August 11, 2026, at 10:30 a.m. ET in Boston. The late clinical-stage biopharmaceutical company focuses on neurodegenerative diseases like ALS and MS. A …
Clene Inc. (CLNN) currently holds a valuation score of 8.10, placing it 156th out of 385 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -1.53, which is significantly below its recent high and above its recent low. However, relevant data …
This article details the shareholder structure of Clene Inc. (CLNN), outlining major individual and institutional holdings. It provides a breakdown of shareholder types, institutional investment over recent quarters, and changes in holdings by key investors. The data indicates Alison Mosca as the largest individual …
This article from TradingKey attempts to provide a revenue breakdown for Clene Inc. (CLNN) by business segments and regional contributions. However, it explicitly states that the relevant data has not been disclosed by the company yet. Therefore, no detailed financial breakdown is available in …
This article provides a detailed cash flow statement for Clene Inc. (CLNN), covering quarterly and annual data for operating, investing, and financing activities. It includes key figures like net income from continuing operations, capital expenditures, and free cash flow, along with explanations of these …
This article from TradingView provides an overview of options volatility for Clene Inc. (CLNN) on the Nasdaq Stock Market. It focuses on implied volatility (IV) and ATM IV term structure, offering charts and tools for assessing risks and developing trading strategies based on market …
Clene Inc. (NASDAQ:CLNN), a clinical-stage pharmaceutical company, is projected by analysts to break even around 2028, turning a profit of US$68m after incurring a final loss in 2027. This breakeven point relies on an aggressive annual growth rate of 65%, which could lead to …
Clene (CLNN) has scheduled its Annual Meeting for May 21, 2026, where shareholders will vote on the election of three Class III directors, the ratification of Deloitte & Touche LLP as the accounting firm, advisory approval for Named Executive Officers' compensation, and an increase …
Clene (CLNN) reported a Q1 2026 net loss of $8.1 million and revenue of $15,000, primarily from dietary supplements. Despite a 41% decrease in operating expenses, the company expects continued losses and will require additional financing to sustain operations beyond one year. Clene plans …
This article provides financial data for Clene Inc. (NASDAQ:CLNN), specifically focusing on its enterprise value to EBIT forward. It appears to be a financial snapshot from TradingView, offering an overview of the company's financial metrics. The original content is primarily navigation and copyright information …
Search by ticker symbol or company name and select a result to open its chart.